Cellectar Biosciences Inc - Company Profile
Powered by 
All the sales intelligence you need on Cellectar Biosciences Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Cellectar Biosciences Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Cellectar Biosciences Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Cellectar Biosciences Inc (Cellectar) is a biopharmaceutical company. It focuses on developing innovative cancer treatments using its proprietary phospholipid ether drug conjugate (PDC) delivery platform, which targets specific tumor cell changes for effective, selective therapy. The company's lead product candidate, iopofosine I 131, delivers iodine-131 directly to cancer cells, minimizing healthy tissue exposure. Iopofosine is being evaluated for several indications, including lymphoplasmacytic lymphoma (LPL), Waldenstrom’s macroglobulinemia (WM), relapsed/refractory multiple myeloma (r/r MM), and relapsed/refractory diffuse large B-cell lymphoma (DLBCL). It is also being studied for neuroblastoma, soft tissue sarcomas, and other pediatric cancers. Cellectar is headquartered in Florham Park, New Jersey, the US.
Headquarters
United States of America
Address
Suite 207, 100 Campus Drive, Florham Park, New Jersey, 07932
Website
www.cellectar.com
Telephone
1 302 6587581
No of Employees
11
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
CLRB (NASD)
EPS
XYZ
Net Income (2024)
XYZ
51.1%
(2024 vs 2023)
Market Cap*
$22.2M
* As of and is in US$
Cellectar Biosciences Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline: | PDC |
| Iopofosine: Waldenstrom's macroglobulinemia, Multiple Myeloma, Diffuse Large B-cell Lymphoma, Ewing’s Sarcoma, Neuroblastoma, Osteosarcoma and Rhabdomyosarcoma |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In December, the company entered into an agreement with Ionetix Corp for Actinium-225 and Astatine-211 to advance targeted alpha therapies. |
| 2025 | Regulatory Approval | In October, the company received rare pediatric disease designation from US FDA for Iopofosine I 131 in relapsed or refractory pediatric high-grade glioma. |
| 2025 | Contracts/Agreements | In September, the company entered into an agreement with Evestia Clinical to support auger-emitting radiopharmaceutical clinical trial in triple-negative breast cancer (TNBC). |
Competitor Comparison
| Key Parameters | Cellectar Biosciences Inc | Exelixis Inc | Seagen Inc | Avelas Biosciences Inc | Lite Strategy Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Florham Park | Alameda | Bothell | La Jolla | San Diego |
| State/Province | New Jersey | California | Washington | California | California |
| No. of Employees | 11 | 1,077 | 3,256 | - | 4 |
| Entity Type | Public | Public | Private | Private | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Douglas J. Swirsky | Chairman | Executive Board | 2017 | 55 |
| James V. Caruso | Chief Executive Officer; Director; President | Executive Board | 2015 | 66 |
| Chad J. Kolean | Vice President; Chief Financial Officer; Secretary | Senior Management | 2022 | 60 |
| Jarrod Longcor | Chief Operating Officer | Senior Management | 2022 | 52 |
| John Neis | Director | Non Executive Board | 2008 | 69 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer